AstraZeneca PLC (AZN) - Long-Term Debt to Capital

This daily price chart for AstraZeneca PLC (AZN) demonstrates the pharmaceutical holding's financial resilience, with liquidity supported by oncology drug sales and a metric of 0.53. The business relies on the defensive nature of demand, which remains indifferent to economic crises. However, AstraZeneca PLC (AZN) faces several challenges: the potential loss of formula exclusivity, pricing pressure from regulators, and uncertainty regarding the outcomes of clinical trials for new products.

Investors assess the margin of safety for AstraZeneca PLC (AZN) through the long-term debt-to-equity ratio, where an increasing value signals heightened financial risk. Given the high scalability of biopharmaceuticals, the long-term debt-to-equity ratio reflects the efficiency of borrowing for costly R&D, determining whether the asset is stable or overleveraged.